{"entity":{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","aka":[],"tldr":"Sung-Bae Kim is a leading Korean breast oncologist on the steering committees of the trastuzumab emtansine and deruxtecan trials.","summary":"Sung-Bae Kim is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in breast cancer. He is a leading Korean breast oncologist who sits on the steering committees of the trastuzumab emtansine and trastuzumab deruxtecan trials, and has been an investigator on many pivotal HER2-positive and triple-negative breast cancer studies, including EMILIA, the DESTINY-Breast trials and immunotherapy combinations. His publications include the DESTINY-Breast03 trial comparing trastuzumab deruxtecan with trastuzumab emtansine in HER2-positive metastatic breast cancer. He co-leads Korean breast cancer research networks, with interests in HER2-positive disease and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20SB%5BAuthor%5D%20Asan%20Medical%20Center%20breast%20cancer"}],"tags":[],"related":[],"cancers":["breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":["her2"],"drugs":["trastuzumab-deruxtecan","trastuzumab-emtansine"],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":["destiny-breast03"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; breast cancer","institutionId":"asan-medical-center","specialisms":["Breast cancer","HER2-positive disease","Triple-negative breast cancer","Antibody-drug conjugates"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20SB%5BAuthor%5D%20Asan%20Medical%20Center%20breast%20cancer"}],"papers":[{"title":"Trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive metastatic breast cancer (DESTINY-Breast03)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115022"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"}]},"route":"/people/kim-sung-bae/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"institution":[{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","route":"/institutions/asan-medical-center/"}],"trial":[{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/"}],"paper":[{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/"},{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/"},{"id":"paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017","kind":"paper","name":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/"},{"id":"paper-park-tils-untreated-early-tnbc-ann-oncol-2019","kind":"paper","name":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","route":"/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/"}]}}